Michele gunsior

Company: Astria Therapeutics

Job title: Senior Director

Seminars:

STAR-0310: A Monoclonal Antibody OX40 Antagonist 11:45 am

OX40 inhibition is a clinically validated mechanism for the treatment of AD Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR-0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic…Read more

day: Day One Discovery Track AM